Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:1117-1120 (17 May), doi:10.1136/bmj.39540.522049.BE (published 14 May 2008)
Jeltsje S Cnossen, research fellow1, Karlijn C Vollebregt, research fellow3, Nynke de Vrieze, medical student1, Gerben ter Riet, associate professor2, Ben W J Mol, professor3, Arie Franx, consultant4, Khalid S Khan, professor5, Joris A M van der Post, professor3
1 Department of General Practice, Academic Medical Center, Meibergdreef 15, 1100 DD, Amsterdam, Netherlands, 2 Horten Center, University of Zurich, Switzerland, 3 Department of Obstetrics and Gynaecology, Academic Medical Center, Amsterdam, Netherlands, 4 Department of Obstetrics and Gynaecology, St Elisabeth Hospital, Tilburg, Netherlands, 5 Department of Obstetrics and Gynaecology, Birmingham Womens Hospital, Birmingham
Correspondence to: J S Cnossen j.s.cnossen{at}amc.uva.nl
Design Systematic review with meta-analysis of data on test accuracy.
Data sources Medline, Embase, Cochrane Library, Medion, checking reference lists of included articles and reviews, contact with authors.
Review methods Without language restrictions, two reviewers independently selected the articles in which the accuracy of blood pressure measurement during pregnancy was evaluated to predict pre-eclampsia. Data were extracted on study characteristics, quality, and results to construct 2x2 tables. Summary receiver operating characteristic curves and likelihood ratios were generated for the various levels and their thresholds.
Results 34 studies, testing 60 599 women (3341 cases of pre-eclampsia), were included. In women at low risk for pre-eclampsia, the areas under the summary receiver operating characteristic curves for blood pressure measurement in the second trimester were 0.68 (95% confidence interval 0.64 to 0.72) for systolic blood pressure, 0.66 (0.59 to 0.72) for diastolic blood pressure, and 0.76 (0.70 to 0.82) for mean arterial pressure. Findings for the first trimester showed a similar pattern. Second trimester mean arterial pressure of 90 mm Hg or more showed a positive likelihood ratio of 3.5 (95% confidence interval 2.0 to 5.0) and a negative likelihood ratio of 0.46 (0.16 to 0.75). In women deemed to be at high risk, a diastolic blood pressure of 75 mm Hg or more at 13 to 20 weeks gestation best predicted pre-eclampsia: positive likelihood ratio 2.8 (1.8 to 3.6), negative likelihood ratio 0.39 (0.18 to 0.71). Additional subgroup analyses did not show improved predictive accuracy.
Conclusion When blood pressure is measured in the first or second trimester of pregnancy, the mean arterial pressure is a better predictor for pre-eclampsia than systolic blood pressure, diastolic blood pressure, or an increase of blood pressure.
Blood pressure measurement is a screening test routinely used in antenatal care to detect or predict hypertensive disease.2 Accurate prediction of women at risk for pre-eclampsia is crucial to judicious allocation of monitoring resources and use of preventive treatment,9 with the prospect of improving maternal and neonatal outcome. Studies investigating the predictive accuracy of blood pressure measurement report conflicting results. In view of these conflicting reports it is uncertain whether blood pressure measurement should be used routinely as a predictive test or used only to diagnose hypertensive disorders in pregnancy once they are suspected. We carried out a systematic review to investigate the accuracy of blood pressure measurement for prediction of pre-eclampsia in pregnant women.
Trained reviewers independently screened titles and abstracts for relevance (JSC and KCV) and full papers for inclusion and data extraction (JSC and NdV). An explanation of extracted clinical, methodological, and statistical data has been published.10 Studies were assessed by one reviewer (JSC) for methodological quality against the quality assessment of diagnostic accuracy studies (QUADAS) criteria14 and randomly checked by a second reviewer (NdV). How we assessed items is summarised on bmj.com. We also assessed application of preventive treatment. For multiple publications of one dataset we included only the most recent or complete study. Disagreements were resolved by consensus or a third reviewer.
Reference standards for pre-eclampsia were a persistent systolic blood pressure of 140 mm Hg or more or a persistent diastolic blood pressure of 90 mm Hg or more, or both, with proteinuria of 0.3 g/day or more or a dipstick result of + or more (30 mg/dl in a single urine sample), or both, new after 20 weeks of gestation. Severe pre-eclampsia was defined as systolic blood pressure of 160 mm Hg or more or diastolic blood pressure of 110 mm Hg or more, or both, with proteinuria 2.0 g/day or more or a dipstick result of +++ or more, or both, of early onset (<34 weeks) gestation. Superimposed pre-eclampsia was defined as the development of proteinuria of 0.3 g/day or more or a dipstick result of + or more after 20 weeks of gestation in chronically hypertensive women. Chronic hypertension was defined as hypertension present before pregnancy or detected before 20 weeks gestation and not resolving within three months after delivery.15
Data synthesis
From the 2x2 tables we calculated sensitivity and specificity and plotted their results in receiver operating characteristic plots. We pooled results among groups of studies measuring similar blood pressure variables (systolic, diastolic, mean arterial, or increase) and similar outcome. We used a bivariate regression model that takes into account the negative correlation between sensitivity and specificity. This method has been extensively described elsewhere and is recently recommended for meta-analysis of diagnostic tests.16 17 Briefly, rather than using a single outcome measure for each study, such as the diagnostic odds ratio, the bivariate model preserves the two dimensional nature of diagnostic data in a single model. This model incorporates the correlation that may exist between sensitivity and specificity within studies owing to possible differences in threshold between studies. When necessary the bivariate model uses a random effects approach for both sensitivity and specificity, allowing for heterogeneity beyond chance due to clinical or methodological differences between studies. In addition the model acknowledges the difference in precision by which sensitivity and specificity have been measured in each study. This means that studies with a larger number of women with pre-eclampsia receive more weight in the calculation of the pooled estimate of sensitivity, whereas studies with more women without pre-eclampsia are more influential in the pooling of specificity. To estimate a summary receiver operating characteristic curve and an area under that curve, we used the results of the model with the smallest Akaikes information criterion (a measure of the goodness of fit of an estimated statistical model).18 This model best accounts for heterogeneity between studies. We calculated areas under the curves in the first trimester for the complete summary receiver operating characteristic curve, which meant extension beyond the available data. We also calculated pooled sensitivities and specificities and derived likelihood ratios thereof.19
We carried out the following subgroup analyses, defined a priori: outcome (severe pre-eclampsia), sample (low risk sample v high risk sample), number of readings (multiple measurement v single measurement), and gestational age at testing (first trimester v second trimester). Sensitivity analyses were done for application of preventive treatment and study quality. We considered studies of high quality when they scored positive on at least four of the following items: prospective design with consecutive recruitment, appropriate reference standard, follow-up greater than 90%, adequate description of the index test, and reporting of preventive treatment.
All statistical analyses were done using SAS 9.1 for Windows (Proc NLMixed in the bivariate model). We used STATA/SE 9.0 0 to draw the receiver operating characteristic plots.
|
|
|
|
In high risk populations a diastolic blood pressure of 75 mm Hg or more at 13 to 20 weeks gestation best predicted pre-eclampsia (positive likelihood ratio 2.8, 1.8 to 3.6; negative likelihood ratio 0.39, 0.18 to 0.71).w26 Another study showed a positive likelihood ratio of 2.8 and negative likelihood ratio of 0.00, but this study had only one case of pre-eclampsia (sensitivity 100%).
In 24 studies it was unclear whether single (in doctors surgery) or multiple (ambulatory blood pressure monitoring during the daytime) readings were reported. When it was assumed that these studies carried out single measurements, the areas under the curves for testing low risk populations in the second trimester remained 0.68 for systolic blood pressure, 0.66 for diastolic blood pressure, and 0.76 for mean arterial pressure. Areas under the curves for blood pressure measurement in the first trimester were 0.66 for systolic blood pressure, 0.67 for diastolic blood pressure, and 0.79 for mean arterial pressure.
Studies that excluded women with chronic hypertension showed positive likelihood ratios for systolic blood pressure of 1.9 (95% confidence interval 0.0 to 3.7), diastolic blood pressure 2.7 (0.0 to 5.5), and mean arterial pressure 2.6 (1.5 to 3.7). Negative likelihood ratios were, respectively, 0.6 (0.4 to 0.6), 0.6 (0.4 to 0.7), and 0.5 (0.3 to 0.8).
Sensitivity analysis on preventive treatment was considered impractical because 25 studies (80%) did not report on it. None of the studies met the criteria for high quality.
Strengths and weaknesses of the review
We carried out extensive literature searches without language restrictions, assessed the quality of the studies and the reporting, and used contemporary statistical methods. Many studies did not distinguish between pre-eclampsia and other hypertensive disorders in pregnancy (fig 1
), nor did many report sufficient information to construct a 2x2 table. Contacting authors did not increase the number of included studies, resulting in a potential loss of relevant data. Quality assessment and subgroup analyses were hindered by unclear reporting in many studies, which is a common problem in diagnostic reviews. Previous studies reported that poor study design and conduct can affect estimates of diagnostic accuracy,21 22 but it is not entirely clear how individual aspects of quality may affect this and to what magnitude in this particular area. Many strategies to account for differences in quality have been applied but none led to estimates that were systematically less optimistic than ignoring quality in meta-analyses of test accuracy studies.23 24 As a result of unclear reporting it was not possible to carry out multivariate subgroup analysis on the basis of individual quality criteria, therefore we reported the overall results. Poor reporting occurred in details of the index test and reference standard, patient selection criteria, and blinding. Definitions of pre-eclampsia have changed over time, with previous definitions including oedema and increases in blood pressure. The measurement of blood pressure was poorly reported, underestimating the importance of recording diastolic blood pressure with Korotkoff phase V as this is more reliably recorded and more closely reflects direct measurement of diastolic blood pressure.25 26 27 Poor reporting of the device used underestimates the importance of its validation for blood pressure measurement during pregnancy.28 29 Poor reporting of patient selection criteria may partly explain the great variability of incidence rates of pre-eclampsia not only between but within the categories of populations considered high risk or low risk. In some of the studies the population that was intended to be recruited differed from the population enrolled. The selection criteria for high risk varied from abnormal uterine artery detected by Doppler ultrasonography to pre-existent disease or mixtures thereof, such as chronic hypertension or diabetes. Large cohort studies (>300 000 women) reflecting unselected populations, however, showed incidence rates of pre-eclampsia between 0.8% and 5.1%.30 31 32 This suggests that small studies of low risk or unselected populations within this review may have been prone to selection bias. Studies that tested in mid-trimester should have taken into account that the predictive accuracy at 14 weeks may differ from that at 27 weeks because by definition no one develops pre-eclampsia in the first half of pregnancy.
Strengths and weaknesses in relation to other studies
A published review in this area was restricted to evaluating risk factors for pre-eclampsia at the first antenatal visit.33 This review included four studies on blood pressure and concluded that the risk of pre-eclampsia was increased in women with a raised diastolic blood pressure (>80 mm Hg) at the first antenatal visit (relative risk 1.48, 95% confidence interval 1.0 to 1.9). Other published reviews did not apply appropriate methods for systematic reviews of screening tests or did not distinguish between different hypertensive disorders.34 35 36 37 38 39 Some of these reviews concluded that an increased mean arterial pressure (
85 mm Hg or
90 mm Hg) predicted transient hypertension rather than pre-eclampsia 34 35 36 and that pregnant women with diastolic blood pressures of 70 mm Hg or more or mean arterial pressures of 80 mm Hg or more in the second trimester have a small risk of developing pre-eclampsia.38
Unanswered questions, future research, and implications
When deciding on whether a predictive test should be applied in clinical practice several things need to be considered: the prevalence of the disease and the predictive accuracy of the test, the cost of the test and its acceptability to patients, and the treatments available for the disease in question. Pre-eclampsia is a disease with relatively low prevalence. A clinically useful test would need to have a great area under the curve (preferably >0.80) or high positive likelihood ratio (>10) and low negative likelihood ratio (<0.10).40 From the results of this review mean arterial pressure still shows the greatest predictive accuracy in the first and second trimesters, with a relatively small likelihood ratio (positive likelihood ratio 3.5; negative likelihood ratio 0.46). In clinical practice measurement of mean arterial pressure at the first antenatal visit may improve the accuracy for estimating risk of pre-eclampsia. Although it will probably not make a clinical impact in isolation, it is highly likely that the prediction of pre-eclampsia will evolve through the development of algorithms that possibly include clinical, biophysical, and biochemical markers. Recently the authors of a large prospective study concluded that maternal variables, together with mean arterial pressure at 11+0 to 13+6 weeks, identify a group at high risk for pre-eclampsia.41 Our data cannot rationalise current obstetrical practice of repeated blood pressure measurements during the first and second trimester in healthy women with a normal blood pressure at the first antenatal visit. A formal cost utility analysis is needed.
Women can experience unnecessary anxiety when being identified at risk of pre-eclampsia after an antenatal test. At present no pharmacological treatment or management strategy (for example, regular ultrasound scanning, early delivery) has been shown to effectively prevent the development of pre-eclampsia. Early antihypertensive treatment has been shown to only prevent severe hypertension, not any other complication. Research into aspirin as a treatment has, however, shown a modest preventive effect (relative risks of 0.9 for pre-eclampsia and 0.9 for fetal growth restriction42) in the absence of any serious side effects. Aspirin is a cheap and readily available preventive treatment. In this instance a false negative test result is potentially more harmful than a false positive test result.
It is imperative to differentiate between mild and severe disease because early or severe pre-eclampsia is associated with raised rates of maternal morbidity and mortality and has pronounced risks for the fetus, such as severe fetal growth restriction.2 43 Future research should also concentrate on the development of algorithms that combine biochemical and biophysical markers, including blood pressure measurement—a diagnostic process used in clinical care. These may help improve the predictive accuracy of the tests to clinically important values.
|
Contributors: All authors conceived and designed the study and drafted and critically revised the manuscript. JSC, KCV, and NdV extracted the data. JSC, NdV, KCV, and JAMvdP analysed and interpreted the data. JSC, NdV, and JAMvdP did the statistical analysis. JSC and JAMvdP are guarantors.
Funding: JSC is supported by a project grant from the Academic Medical Centre fellowships for clinical guidelines.
Competing interests: None declared.
Ethical approval: Not required.
Provenance and peer review: Not commissioned; externally peer reviewed.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
What can you learn from this BMJ paper? Read Leanne Tite's Paper+